HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer

Yizhou Zhang, Hanrong Li, Chao Lv, Baokang Wu, Yang Yu, Chongli Zhong, Qi Lang, Zhiyun Liang, Yang Li, Yu Shi, Jian Jian, Feng Xu, Yu TianInternational Journal of Oncology 2022 · DOI

Abstract

Advanced gallbladder cancer (GBC) is a highly malignant biliary tract cancer associated with poor prognosis and high mortality. This study investigates the role of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2), also known as B7-H7, in GBC progression. Through immunohistochemical analysis of 89 patient samples, researchers found that HHLA2 expression correlates with advanced disease stages and significantly reduced overall survival. Functional assays and xenograft models demonstrated that HHLA2 promotes cell proliferation, migration, invasion, and the epithelial-mesenchymal transition (EMT). Furthermore, the study identifies a regulatory axis where the long non-coding RNA H19 promotes HHLA2 expression, suggesting that HHLA2 is a potential therapeutic target for this aggressive disease.

Introduction

Gallbladder cancer (GBC) is notoriously aggressive, often diagnosed at late stages when treatment options are limited. While the B7 family of proteins is known to regulate immune responses and cancer invasion, the specific role of HHLA2 in GBC was previously unclear. This research sought to determine if HHLA2 expression correlates with clinical outcomes and to uncover the molecular mechanisms—specifically its relationship with the oncogenic lncRNA H19—that allow HHLA2 to promote tumor growth and metastasis.

Methods and Materials

The researchers employed a multi-disciplinary approach combining clinical pathology, cellular biology, and animal models:

  • Clinical Correlation: Immunohistochemistry (IHC) was performed on 89 GBC specimens from Shengjing Hospital of China Medical University to map HHLA2 expression against clinical parameters like Nevin stage and overall survival.
  • Genetic Manipulation: Lentiviral vectors were used to either overexpress or knock down (via shRNA) HHLA2 and lncRNA H19 in the GBC-SD cell line.
  • Functional Assays: Migration and invasion were measured via wound-healing and Transwell assays; proliferation was assessed using EdU assays; and EMT markers (E-cadherin, N-cadherin, vimentin) were tracked via Western blotting and immunofluorescence.
  • In Vivo Validation: A xenograft mouse model using BALB/c nude mice was established to observe the impact of HHLA2 levels on tumor growth over 18 days.

Results

Clinical Significance and Prognosis

HHLA2 expression was found to scale with disease progression. Higher levels were significantly associated with advanced Nevin and AJCC stages, increased tumor invasion, and regional lymph node metastasis. Most critically, patients in the "HHLA2-high" group faced significantly shorter survival times compared to the "HHLA2-low" group (P=0.008), with a calculated Hazard Ratio of 2.15.

Clinical correlation and survival analysis of HHLA2 expression in GBC patients

HHLA2 as a Driver of EMT

The study demonstrated that HHLA2 directly promotes the transition of cancer cells from a stationary epithelial state to a mobile, invasive mesenchymal state. Immunofluorescence staining confirmed that HHLA2 overexpression leads to a decrease in the epithelial "glue" protein E-cadherin and a corresponding increase in mesenchymal markers such as N-cadherin, vimentin, and α-SMA.

Immunofluorescence staining of EMT markers following HHLA2 overexpression in GBC-SD cells

The H19-HHLA2 Axis

The researchers identified a regulatory hierarchy where lncRNA H19 acts upstream to increase HHLA2 expression. Critically, knocking down HHLA2 suppressed the aggressive phenotypes induced by both TGF-β1 (a potent EMT inducer) and H19 overexpression. This suggests that HHLA2 is a key effector and a potential therapeutic "bottleneck" that could be targeted to inhibit GBC progression.

Conclusion

These findings establish HHLA2 as a significant driver of GBC progression and a valuable prognostic biomarker. By promoting EMT through the H19-HHLA2 axis, this protein facilitates tumor growth and metastasis. Targeting HHLA2 could offer a new therapeutic avenue for treating this aggressive malignancy. Future research should investigate the specific signaling intermediates, such as the Wnt/β-catenin pathway, and explore HHLA2's role within the GBC immune microenvironment.

Summary updated

Abstract

Advanced gallbladder cancer (GBC) is one of the most malignant of all types of biliary tract cancers that is associated with poor prognosis and high mortality. Accumulating evidence suggest that the B7 family of proteins serve an essential role in various types of cancers, including GBC. However, the potential function and regulatory mechanism of human endogenous retrovirus‑H long terminal repeat‑associating protein 2 (HHLA2; also known as B7‑H7 or B7H5) in GBC remain poorly understood. In the present study, immunohistochemistry was used to examine the expression pattern of HHLA2 in samples from 89 patients with GBC. The possible association between HHLA2 expression and the clinicopathological parameters, including prognosis, were then assessed. Using lentiviruses, overexpression of HHLA2 plasmid or short‑hairpin RNA (shRNA) of HHLA2 were transfected into GBC‑SD cells to overexpress or knock down HHLA2 expression, respectively. The effects of HHLA2 overexpression and knockdown on the epithelial‑mesenchymal transition (EMT) process on GBC‑SD cells were measured by the western blotting and immunofluorescence staining of collagen I, N‑cadherin, E‑cadherin, vimentin and α‑SMA. By contrast, changes in cell proliferation were measured using EdU assay. Cell invasion and migration were assessed using Transwell and wound‑healing assays, respectively. In addition, a xenograft mouse model was established to evaluate the tumorigenic ability of the GBC cell line <i>in vivo</i> after stable transfection with lentivirus for HHLA2 overexpression or shRNA for HHLA2 knockdown. The regulatory relationships among TGF‑β1, long non‑coding RNA (lncRNA) H19 (H19) and HHLA2 were then investigated. The mRNA expression of lncRNA H19 were assessed using reverse transcription‑quantitative PCR, whereas the expression levels of HHLA2 were detected by western blotting and immunofluorescence staining. HHLA2 expression was found to gradually increase as the stages of the GBC samples become more advanced. In addition, the expression level of HHLA2 was calculated to be positively associated with the Nevin stage, American Joint Committee on Cancer stage, tumor invasion and regional lymph node metastasis but was negatively associated with the overall patient survival (OS). <i>In vitro</i> experiments demonstrated that overexpression of HHLA2 promoted GBC migration, invasion, proliferation and EMT, whereas <i>in vivo</i> experiments found a promoting role of HHLA2 overexpression on GBC tumor growth. After transfection with lentiviruses encoding the overexpression plasmid of lncRNA H19, GBC migration, invasion, proliferation and EMT were increased. By contrast, knocking down HHLA2 expression suppressed TGF‑β1‑ or lncRNA H19 overexpression‑induced GBC migration, invasion, proliferation and EMT. In addition, HHLA2 knockdown significantly reduced the sizes of the GBC tumors <i>in vivo</i>. These results suggest that HHLA2 overexpression can promote GBC progression. Conversely, ablation of HHLA2 expression inhibited both TGF‑β1‑ and lncRNA H19‑induced GBC progression, suggesting that HHLA2 is a potential therapeutic target for this disease.
BibTeX
@article{zhang2022hhla,
  author = {Yizhou Zhang and Hanrong Li and Chao Lv and Baokang Wu and Yang Yu and Chongli Zhong and Qi Lang and Zhiyun Liang and Yang Li and Yu Shi and Jian Jian and Feng Xu and Yu Tian},
  title = {{HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer}},
  journal = {International Journal of Oncology},
  year = {2022},
  doi = {10.3892/ijo.2022.5402},
}
Figure